Pharmacological aspects of neonatal antidepressant withdrawal.

  title={Pharmacological aspects of neonatal antidepressant withdrawal.},
  author={Peter J G Ter Horst and Frank G. A. Jansman and Richard A. van Lingen and Jennifer Smit and Lolkje de Jong-van den Berg and Jacobus R. B. J. Brouwers},
  journal={Obstetrical & gynecological survey},
  volume={63 4},
UNLABELLED Depression is common in reproductive age women, and continued pharmacologic treatment of depression during pregnancy may be necessary to prevent relapse, which could be harmful for both the fetus and the mother. Although data on drug safety are imperfect and incomplete, the benefits of antidepressant therapy during pregnancy generally outweigh the risks. Neonates who are exposed to antidepressant medications during gestation are at increased risk to have neonatal withdrawal syndrome… CONTINUE READING

From This Paper

Figures and tables from this paper.


Publications citing this paper.
Showing 1-10 of 12 extracted citations

The use of psychotropic medication during pregnancy: how about the newborn?

Neuropsychiatric disease and treatment • 2013
View 12 Excerpts
Highly Influenced

Adapted Finnegan scoring list for observation of anti-depressant exposed infants.

The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians • 2015
View 1 Excerpt


Publications referenced by this paper.
Showing 1-10 of 163 references

Neonatal effects of selective serotonin receptor inhibitors (SSRI) exposure 278 Obstetrical and Gynecological Survey during pregnancy

P Bot, J Stappen van der, B. Seminmekrot
Arch Dis Child Fetal Neonatal Ed • 2006

Similar Papers

Loading similar papers…